Go Pro

B. Metzler seel. Sohn & Co. AG Cuts Position in Synopsys, Inc. $SNPS

Synopsys logo with Technology background
Image from MarketBeat Media, LLC.

B. Metzler seel. Sohn & Co. AG decreased its stake in Synopsys, Inc. (NASDAQ:SNPS - Free Report) by 20.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,863 shares of the semiconductor company's stock after selling 3,465 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Synopsys were worth $6,184,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new stake in Synopsys during the second quarter worth $7,228,099,000. State Street Corp increased its position in shares of Synopsys by 0.3% in the fourth quarter. State Street Corp now owns 8,788,890 shares of the semiconductor company's stock valued at $4,128,317,000 after buying an additional 28,532 shares in the last quarter. Morgan Stanley increased its position in shares of Synopsys by 2.5% in the fourth quarter. Morgan Stanley now owns 4,573,980 shares of the semiconductor company's stock valued at $2,148,491,000 after buying an additional 109,917 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Synopsys by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 4,310,846 shares of the semiconductor company's stock worth $2,017,256,000 after buying an additional 54,329 shares during the last quarter. Finally, Van ECK Associates Corp raised its stake in shares of Synopsys by 19.7% during the 2nd quarter. Van ECK Associates Corp now owns 3,457,249 shares of the semiconductor company's stock worth $1,542,175,000 after buying an additional 569,687 shares during the last quarter. Hedge funds and other institutional investors own 85.47% of the company's stock.

Insiders Place Their Bets

In related news, CFO Shelagh Glaser sold 3,394 shares of the company's stock in a transaction on Friday, June 12th. The stock was sold at an average price of $450.02, for a total value of $1,527,367.88. Following the completion of the transaction, the chief financial officer directly owned 14,358 shares in the company, valued at approximately $6,461,387.16. This represents a 19.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Aart de Geus sold 25,000 shares of the company's stock in a transaction on Monday, August 31st. The shares were sold at an average price of $441.76, for a total value of $11,044,000.00. Following the completion of the transaction, the insider owned 120,421 shares of the company's stock, valued at $53,197,180.96. The trade was a 17.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 92,638 shares of company stock valued at $40,747,732 in the last quarter. 0.56% of the stock is currently owned by company insiders.

Synopsys Price Performance

Synopsys stock opened at $416.31 on Friday. The stock has a market capitalization of $79.78 billion, a P/E ratio of 73.55, a P/E/G ratio of 2.28 and a beta of 1.23. Synopsys, Inc. has a 12-month low of $366.00 and a 12-month high of $615.79. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.34 and a quick ratio of 1.24. The firm's 50-day moving average is $413.48 and its two-hundred day moving average is $439.79.

Synopsys (NASDAQ:SNPS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 26th. The semiconductor company reported $3.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.67 by $0.24. Synopsys had a net margin of 11.43% and a return on equity of 6.24%. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.44 billion. During the same quarter in the prior year, the firm posted $3.39 earnings per share. The company's quarterly revenue was up 42.4% compared to the same quarter last year. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. Equities analysts predict that Synopsys, Inc. will post 10.97 earnings per share for the current year.

Analyst Ratings Changes

SNPS has been the topic of a number of research reports. Rosenblatt Securities reissued a "buy" rating and issued a $575.00 price objective on shares of Synopsys in a research note on Tuesday, August 25th. Morgan Stanley reduced their price target on shares of Synopsys from $525.00 to $500.00 and set an "equal weight" rating on the stock in a report on Wednesday, August 19th. Wells Fargo & Company lowered their price target on shares of Synopsys from $535.00 to $450.00 and set an "equal weight" rating on the stock in a research report on Tuesday, August 11th. Benchmark reissued a "buy" rating and set a $570.00 price objective on shares of Synopsys in a research note on Thursday, August 27th. Finally, Zacks Research downgraded Synopsys from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 21st. Twelve investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $561.28.

View Our Latest Stock Analysis on SNPS

Synopsys Company Profile

(Free Report)

Synopsys, Inc is a leading provider of electronic design automation (EDA) software and semiconductor intellectual property (IP) used to design, verify and manufacture integrated circuits and complex systems-on-chip (SoCs). Its product portfolio spans tools and technologies for front‑end design and synthesis, simulation and verification, physical implementation and signoff, and design-for-manufacturability, enabling chip designers to move from architecture through tape‑out.

In addition to core EDA offerings, Synopsys supplies a broad set of semiconductor IP building blocks — such as interface, memory and analog/mixed-signal cores — that customers integrate into SoCs to accelerate development.

See Also

Want to see what other hedge funds are holding SNPS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synopsys, Inc. (NASDAQ:SNPS - Free Report).

Institutional Ownership by Quarter for Synopsys (NASDAQ:SNPS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Synopsys Right Now?

Before you consider Synopsys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Synopsys wasn't on the list.

While Synopsys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines